ArticleNature communications2026
Programmable nanomicelles rewire myeloid immunity for durable control of primary and metastatic breast cancer.
Jie Yang, Di Chang, Yingbo Li, Zuoyu Xu, Daoshuang Li, Xiaoxuan Xu, Zhiqi Zhang, Yize Li, Jianqiong Zhang, Jinbing Xie and 2 more
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Jie Yang *Department of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.ORCID http://orcid.org/0000-0002-8636-2015 Di Chang *Department of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.
Yingbo LiDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.ORCID http://orcid.org/0000-0003-0453-4862 Zuoyu XuDepartment of Nuclear Medicine, The Fourth Hospital of Harbin Medical University, Harbin, China.
Daoshuang LiDepartment of Ultrasound, The Fourth Hospital of Harbin Medical University, Harbin, China.
Xiaoxuan XuDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.
Zhiqi ZhangDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.ORCID http://orcid.org/0000-0003-3390-1254 Yize LiDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.ORCID http://orcid.org/0009-0003-6385-0942 Jianqiong ZhangDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.
Jinbing XieDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.ORCID http://orcid.org/0000-0002-6071-0878 Zebin XiaoDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China.ORCID http://orcid.org/0000-0002-3311-7403 Shenghong JuDepartment of Radiology, Zhongda Hospital, School of Medicine, Nurturing Center of Jiangsu Province for the State Laboratory of AI Imaging and Interventional Radiology, Southeast University, Nanjing, China. jsh@seu.edu.cn.ORCID http://orcid.org/0000-0001-5041-7865 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Immunosuppressive myeloid cells, including immature dendritic cells (DC) and tumor-promoting macrophages, drive tumor progression and immune evasion. Reprogramming these cells into immune effectors remains challenging. Here, we present a programmable nanomicelle platform that reconfigures myeloid immunity to combat both primary and metastatic breast cancer (BC). The nanomicelles co-deliver photosensitizers (IR825), anti-PD-L1 antibodies, and antagomiR-182 with spatiotemporal precision. Upon activation, they induce immunogenic cell death, promoting DC maturation to enhance antigen presentation. Concurrently, miR-182 inhibition repolarizes M2-like macrophages into M1-like phenotypes via the TLR4/MYD88/NF-κB pathway. This dual reprogramming enhances CD8
Indexed as
Breast NeoplasmsMicellesMyeloid CellsAnimalsCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsFemaleHumansImmunotherapyMacrophagesMiceMyeloid Differentiation Factor 88NanoparticlesNeoplasm MetastasisXenograft Model Antitumor AssaysMicellesMyeloid Differentiation Factor 88
Identifiers
PMID41844653
PMCPMC13144373
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390